Publications by authors named "J Sugita"
Article Synopsis
- HLA-haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide (PTCy-haplo) is becoming a safer and more available option compared to matched unrelated donor (MUD) transplants for acute myeloid leukemia (AML).
- * A nationwide study found that while PTCy-haplo has a slower hematopoietic recovery and higher infection-related deaths, it also shows lower rates of severe graft-versus-host disease (GVHD) compared to ATG-free MUD transplants.
- * Overall survival rates were similar across all transplant types, suggesting that PTCy-haplo could be a viable option for AML patients lacking an HLA-matched donor.
Systemic corticosteroid therapy is a well-established first-line treatment for grades II-IV acute graft-versus-host disease (aGVHD). Recently, several developments have occurred, including the introduction of transplantation from human leukocyte antigen (HLA) haploidentical donors using post-transplant cyclophosphamide (PTCY-Haplo), and improvements in prognosis after cord blood transplantation (CBT) in Japan. This study aimed to analyze the association between donor sources and outcomes in patients with aGVHD.
View Article and Find Full Text PDFArticle Synopsis
- * Researchers tested a target spectral camera to accurately measure blood pressure using images of 215 adults' palms and faces, analyzing pulse transit time (PTT) to estimate BP.
- * The study found a machine learning model could classify hypertension with up to 95% accuracy using just one second of video footage, highlighting the potential for more accessible and cuffless blood pressure monitoring methods.
Allogeneic hematopoietic cell transplantation (HCT) potentially provides a cure for patients with acute myeloid leukemia (AML) who are unlikely to be cured with chemotherapy alone. Previously, human leukocyte antigen (HLA)-matched related donors were used exclusively, which made the procedure available for a limited proportion of patients. The introduction of high-resolution HLA-typing technology, innovations in immunosuppressive therapy, and improved supportive care measures have significantly changed the situation.
View Article and Find Full Text PDF